Precision Biosciences (DTIL) Other Non-Current Liabilities (2020 - 2026)

Precision Biosciences (DTIL) has 7 years of Other Non-Current Liabilities data on file, last reported at $22.8 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 128.02% year-over-year to $22.8 million in Q1 2026; TTM through Mar 2026 was $22.8 million, a 128.02% increase from a year earlier, with the FY2025 full-year figure at $15.7 million, up 56.95% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $22.8 million, up from $15.7 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for DTIL reached as high as $22.8 million in Q1 2026 and fell as low as $34000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $8.6 million across 5 years, with a median of $10.0 million in 2022.
• Across the five-year window, Other Non-Current Liabilities soared 29311.76% in 2023 and tumbled 98.12% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $201000.0 in 2022, then plunged by 36.32% to $128000.0 in 2023, then jumped by 7712.5% to $10.0 million in 2024, then surged by 56.95% to $15.7 million in 2025, then jumped by 45.28% to $22.8 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $22.8 million in Q1 2026, $15.7 million in Q4 2025, and $227000.0 in Q3 2025.